The bill, H.B. No. 3086, amends the Health and Safety Code to enhance reporting requirements for pharmaceutical drug manufacturers regarding prescription drug costs. It mandates that manufacturers submit an annual report detailing the wholesale acquisition costs of FDA-approved prescription drugs sold in Texas. Additionally, if a drug's wholesale acquisition cost increases by 40% or more over the past three years or by 15% or more in the previous year, the manufacturer must provide specific information in the report, including whether the drug is a brand name or generic, factors contributing to the cost increase, research and development costs, and details about drugs approved or losing patent exclusivity in the last three years.

The bill also modifies the timeline for the publication of cost increase information by the department, requiring it to be published within 60 days of receiving the report. Furthermore, it establishes that the department shall assess administrative penalties for violations of this chapter, replacing the previous provision that allowed for discretion in assessing penalties. The bill repeals Section 441.0053 and requires the executive commissioner of the Health and Human Services Commission to adopt necessary rules for implementation. The act is set to take effect on September 1, 2025.

Statutes affected:
Introduced: Health and Safety Code 441.0051, Health and Safety Code 441.0054, Health and Safety Code 441.0102, Health and Safety Code 441.0053 (Health and Safety Code 441)